Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Flavopiridol, Oxaliplatin, Fluorouracil, and Leucovorin in Treating Patients With Advanced Solid Tumors

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase I Treatment Active 18 and over NCI MSKCC-03146 6365, NCI-6365, NCT00080990

Objectives

Primary

1. Determine the maximum tolerated dose of flavopiridol when given in combination with oxaliplatin, fluorouracil, and leucovorin calcium in patients with advanced solid tumors.
2. Determine the pharmacokinetics of this regimen in these patients.
3. Determine, preliminarily, the therapeutic activity of this regimen in these patients.

Secondary

1. Determine the dose-limiting toxicity and the recommended phase II dose of flavopiridol when administered with this regimen in these patients.
2. Determine the safety and tolerability of this regimen in these patients.
3. Correlate p21, p53, and apoptotic markers with response in patients treated with this regimen.

Entry Criteria

Disease Characteristics:

• Histologically confirmed advanced solid tumor
  • Refractory to standard therapy or no standard therapy exists



• Evaluable disease



• No known untreated CNS metastases
  • Patients who have undergone local treatment for brain metastases and whose brain metastases are stable by repeat imaging study performed ≤ 4 weeks after treatment are allowed



• No primary CNS tumors

Prior/Concurrent Therapy:

Biologic therapy

• At least 2 weeks since prior immunotherapy

Chemotherapy

• At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)
• No prior flavopiridol

Endocrine therapy

• Not specified

Radiotherapy

• At least 2 weeks since prior radiotherapy

Surgery

• Not specified

Other

• Recovered from all prior therapy
• No concurrent therapy for thrombosis
  • Prophylaxis for central lines or deep vein thrombosis allowed
• No other concurrent investigational medications
• No concurrent vitamins, antioxidants, or herbal preparations and supplements
  • Concurrent single-tablet multivitamin allowed

Patient Characteristics:

Age

• 18 and over

Performance status

• Karnofsky 60-100%

Life expectancy

• Not specified

Hematopoietic

• WBC ≥ 3,500/mm³
• Neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³

Hepatic

• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN for liver metastases)

Renal

• Creatinine ≤ 1.5 mg/dL

Cardiovascular

• No cardiac arrhythmias within the past 6 months
• No congestive heart failure within the past 6 months
• No myocardial infarction within the past 6 months
• No arterial or venous thrombosis within the past year

Other

• No peripheral neuropathy > grade 1
• No other medical condition that would preclude study participation
• No serious or uncontrolled infection
• HIV negative
• Not pregnant or nursing
  • No nursing during and for 2 months after study participation
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study participation

Expected Enrollment

A total of 3-46 patients will be accrued for this study within approximately 2 years.

Outcomes

Recommended phase II dose as assessed by NCI toxicity scale during 4-6 weeks of treatment

Response as assessed by RECIST criteria every 8 weeks

Outline

This is a non-randomized, open-label, dose-escalation study of flavopiridol.

Patients receive flavopiridol IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose.

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Gary K. Schwartz, MD, Protocol chair		Ph: 212-639-8324; 800-525-2225

U.S.A.
New York
	New York
	Memorial Sloan-Kettering Cancer Center
		Archie Tse, MD, PhD	Ph:  212-639-7599 800-525-2225
			Email: tsea@mskcc.org
		Gary K. Schwartz, MD	Ph:  212-639-8324 800-525-2225

Registry Information
Official Title		An Open Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered with Oxaliplatin and Fluorouracil/Leucovorin in Patients with Advanced Solid Tumors
Trial Start Date		2004-02-17
Trial Completion Date		2004-10-04 (estimated)
Registered in ClinicalTrials.gov		NCT00080990
Date Submitted to PDQ		2004-02-20
Information Last Verified		2008-12-14
NCI Grant/Contract Number		CA08748

Back to Top